Intech Biopharm
Taipei, Taiwan· Est.
Taiwan‑based inhalation‑drug specialist delivering innovative MDI solutions for asthma and COPD.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan‑based inhalation‑drug specialist delivering innovative MDI solutions for asthma and COPD.
Respiratory
Technology Platform
iLEF (Inhaled Low Ethanol Formulation) is a metered‑dose inhaler platform that uses a low‑ethanol co‑solvent to produce stable, fine‑particle aerosols with controlled aerodynamic size for deep lung delivery.
Opportunities
Expanding demand for inhalation therapies in Asia‑Pacific and the ability to launch differentiated generic MDIs provide strong growth potential.
Risk Factors
Regulatory approval timelines, competition from established global inhalation manufacturers, and limited disclosed clinical data pose significant risks.
Competitive Landscape
Major competitors include GSK, AstraZeneca, and Boehringer Ingleheim; Intech differentiates through its low‑ethanol formulation technology and focus on high‑entry‑barrier generics.